These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18635436)

  • 1. Reducing antibody levels in patients undergoing transplantation.
    Shapiro R
    N Engl J Med; 2008 Jul; 359(3):305-6. PubMed ID: 18635436
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab and intravenous immune globulin for desensitization during renal transplantation.
    Vo AA; Lukovsky M; Toyoda M; Wang J; Reinsmoen NL; Lai CH; Peng A; Villicana R; Jordan SC
    N Engl J Med; 2008 Jul; 359(3):242-51. PubMed ID: 18635429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of intravenous immune globulin and rituximab for desensitization of highly human leukocyte antigen-sensitized patients awaiting kidney transplantation.
    Rehman S; Meier-Kriesche HU; Scornik J
    Transplantation; 2010 Oct; 90(8):932; author reply 932-3. PubMed ID: 20962612
    [No Abstract]   [Full Text] [Related]  

  • 4. Desensitization during renal transplantation.
    Fourtounas C; Mouzaki A; Vlachojannis JG
    N Engl J Med; 2008 Oct; 359(16):1731; author reply 1731-2. PubMed ID: 18923177
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of sensitized patients awaiting renal transplantation: does sequential therapy of intravenous immunoglobulin and simvastatin offer a solution?
    Mahmoud KM; Sobh MA; El Shenawy F; Isamil AM; El-Magd MA; Hassan NA; El-Agroudy AE; Sheashaa HA; Opelz G; Ghoneim MA
    Eur J Pharmacol; 2007 Apr; 561(1-3):202-5. PubMed ID: 17296177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibody-mediated acute rejection].
    Lefaucheur C; Nochy D; Glotz D
    Nephrol Ther; 2008 Oct; 4 Suppl 3():S188-91. PubMed ID: 19000885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presensitization: the problem and its management.
    Jordan SC; Pescovitz MD
    Clin J Am Soc Nephrol; 2006 May; 1(3):421-32. PubMed ID: 17699241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of highly sensitized patients: capitol medical center experience.
    Amante AJ; Ejercito R
    Transplant Proc; 2008 Sep; 40(7):2274-80. PubMed ID: 18790211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplantation across previously incompatible immunological barriers.
    Magee CC
    Transpl Int; 2006 Feb; 19(2):87-97. PubMed ID: 16441356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA desensitization in pediatric heart transplant candidates: efficacy of rituximab and IVIg.
    Schumacher KR; Ramon DS; Kamoun M; Caruthers R; Gajarski RJ
    J Heart Lung Transplant; 2012 Sep; 31(9):1041-2. PubMed ID: 22748817
    [No Abstract]   [Full Text] [Related]  

  • 11. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.
    Reinsmoen NL; Lai CH; Vo A; Cao K; Ong G; Naim M; Wang Q; Jordan SC
    Transplantation; 2008 Sep; 86(6):820-5. PubMed ID: 18813107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of the highly sensitized patient.
    Claas FH; Doxiadis II
    Curr Opin Immunol; 2009 Oct; 21(5):569-72. PubMed ID: 19682882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HLA-incompatibility and kidney transplant: a question of desensitization].
    Grosjean F
    G Ital Nefrol; 2011; 28(6):581. PubMed ID: 22167608
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravenous immunoglobulins and kidney transplantation in patients with anti-HLA antibodies.
    Glotz D; Antoine C; Haymann JP; Julia P; Duboust A; Bariéty J
    Adv Nephrol Necker Hosp; 2000; 30():221-33. PubMed ID: 11068645
    [No Abstract]   [Full Text] [Related]  

  • 15. ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab.
    Chikaraishi T; Sasaki H; Tsutsumi H; Miyano S; Nakazawa R; Nakano T; Kitajima K; Kudo H; Takahashi T; Sato Y; Kimura K
    Transplant Proc; 2008 Dec; 40(10):3445-7. PubMed ID: 19100409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates.
    Reinsmoen NL; Lai CH; Vo A; Jordan SC
    Discov Med; 2012 Apr; 13(71):267-73. PubMed ID: 22541614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for pemphigus vulgaris.
    Joly P; D'Incan M; Musette P
    N Engl J Med; 2007 Feb; 356(5):521; author reply 521-2. PubMed ID: 17267915
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
    Al Meshari K
    Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
    [No Abstract]   [Full Text] [Related]  

  • 19. Excellent renal allograft survival in donor-specific antibody transplant patients--role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Dhanda R; Shah Y; Bardapure M; Bhattacharjya S; Sharma AK
    Transplantation; 2009 Aug; 88(3):444. PubMed ID: 19667954
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.